STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services through a network of approximately 50 contract sterilization and laboratory facilities.The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.
Company profile
Website
CEO
Walter M. Rosebrough
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
SEC CIK
Corporate docs
IRS number
341482024
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
26 Mar 21
424B5
Prospectus supplement for primary offering
24 Mar 21
S-3ASR
Automatic shelf registration
23 Mar 21
15-12B/A
Securities registration termination (amended)
17 Nov 15
15-12B
Securities registration termination
16 Nov 15
EFFECT
Notice of effectiveness
12 Nov 15
8-K
Completion of Acquisition or Disposition of Assets
6 Nov 15
POS AM
Prospectus update (post-effective amendment)
6 Nov 15
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Nov 15
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Nov 15
Latest ownership filings
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 4.34 bn |
Total shares | 32.07 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Fruth Investment Management | 12.65 k | $2.85 mm |
Cibc World Markets | 11.63 k | $2.62 bn |
Penobscot Investment Management | 7.64 k | $1.72 bn |
AlphaMark Advisors | 150.00 | $34.00 k |